US authorises increased production of Takeda’s ADHD drug to address shortages
The US Drug Enforcement Administration has increased the production limit for Takeda Pharmaceuticals’ ADHD drug Vyvanse and its generics have increased in price by about 24 per cent to address the ongoing shortage of the drug in the United States.
POPULAR POSTS
Bluetongue outbreak in a Portuguese sheep farm has broken out
September 19, 2024
Austria says disaster fund to rise to 1 billion euros
September 19, 2024
Portugal gets help from Spain and Morocco in response to fires
September 19, 2024
Drought reduces Amazon rivers to historic lows
September 19, 2024
LIVE STREAM